Biomarin Pharmaceutical Inc
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
BLTS Bright Lights Acquisition Corp
MMM 3M Co
STRR Star Equity Holdings Inc
BMY Bristol-Myers Squibb Co
BCTX Briacell Therapeutics Corp
ENV Envestnet Inc
CDR-B Cedar Realty Trust Inc
EVIO EVIO Inc
WCC Wesco International Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Closing Price
$80.97
Day's Change
2.11 (2.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
81.20
Day's Low
78.65
Volume
(Light)
Volume:
659,473

10-day average volume:
952,848
659,473
  • Prev Close
    78.86
  • Today's Open
    79.00
  • Day's Range
    78.65-81.20
  • Avg Vol (10-day)
    952.8K
  • Last (time)
    4:00p ET 05/27/22
  • Last (size)
    1
  • 52-Wk Range
    71.59 - 94.20
    LowHigh
  • (10/27/21 - 02/10/22)
    13.10%
  • 33.7%
  • Market Cap
    15.0B
  • Shares Outstanding
    185.0M
  • 0.15
  • 513.18x
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.4
  • 96.65
  • (% of float 05/15/22)
    6.61

Latest News

May 18, 2022
9:01 am ET
Newsfile
May 05, 2022
8:29 am ET
PR Newswire
April 13, 2022
3:31 pm ET
Globe Newswire
March 25, 2022
6:01 pm ET
Newsfile
March 17, 2022
8:31 am ET
PR Newswire
March 04, 2022
9:00 pm ET
Globe Newswire
January 10, 2022
7:55 am ET
MarketWatch
November 24, 2021
11:21 am ET
Zacks
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.